ALSO NOTED: Fuji to buy Japanese drug maker for $1.44B; BMS bumps CEO Cornelius up to chairman

> Fujifilm Holdings offered as much as $1.44 billion for midsize Japanese drug maker Toyama Chemical, in another mark of Fuji's shift toward medical products. Report | Report

> Bristol-Myers Squibb added "chairman" to CEO James Cornelius' title and duties; he replaces James D. Robinson III, who's served as non-executive chairman since 2005. Release

> A very small study presented to the American Society of Clinical Oncology showed that Pfizer's Sutent drug may be linked to more instances of heart failure than previously thought. Report

> Nastech Pharma announced plans to cut 50 jobs as part of a corporate restructuring plan; the cuts are expected to save $11 million in 2008. Release

> Taisho Pharma says it's mounting a $251.4 million tender offer for Biofermin  Pharmaceutical. Release

> Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal antibody product. Report

> Investors have focused their attention on Oxford BioMedica, a struggling UK developer that is the hotly rumored takeover target of Sanofi-Aventis. Report

> One of the top lawmakers in Massachusetts is predicting swift passage of a new bill that would provide a billion dollars in incentives to the life sciences industry in the state. Report

And Finally... A BusinessWeek Pro and Con: Should pharma freebies be history? Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.